Technical Analysis for XTLB - XTL Biopharmaceuticals Ltd.

Grade Last Price % Change Price Change
D 3.0 -4.46% -0.14
XTLB closed down 4.46 percent on Tuesday, April 20, 2021, on 7 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical XTLB trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -4.46%
NR7 Range Contraction -4.46%
Inside Day Range Contraction -4.46%
Oversold Stochastic Weakness -4.46%
Hammer Candlestick Bullish -6.25%
Older End-of-Day Signals for XTLB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% 5 days ago
Up 2% 5 days ago
Up 1% 5 days ago
Up 2% 6 days ago
Up 1% 6 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


XTL Biopharmaceuticals Ltd. Description

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. It is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C. The company's lead drug candidate is recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma blood cancer, as well as for the treatment of severe anemia. The rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma blood cancer. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases, with focus on schizophrenia. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Herzliya, Israel.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Clinical Development Natural Sciences Pharmaceutical Products Pharmacy Medication Schizophrenia FDA Multiple Myeloma Anemia Biopharmaceuticals Hepatitis C Drug Design Orphan Drug Antipsychotic Erythropoietin

Is XTLB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 6.11
52 Week Low 0.92
Average Volume 343,798
200-Day Moving Average 2.55
50-Day Moving Average 3.38
20-Day Moving Average 3.33
10-Day Moving Average 3.22
Average True Range 0.23
ADX 25.79
+DI 19.12
-DI 20.48
Chandelier Exit (Long, 3 ATRs ) 3.11
Chandelier Exit (Short, 3 ATRs ) 3.64
Upper Bollinger Band 3.64
Lower Bollinger Band 3.02
Percent B (%b) -0.03
BandWidth 18.60
MACD Line -0.07
MACD Signal Line -0.03
MACD Histogram -0.0372
Fundamentals Value
Market Cap 15.43 Million
Num Shares 5.14 Million
EPS 0.20
Price-to-Earnings (P/E) Ratio 15.00
Price-to-Sales 0.00
Price-to-Book 2.12
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.32
Resistance 3 (R3) 3.33 3.25 3.26
Resistance 2 (R2) 3.25 3.17 3.24 3.24
Resistance 1 (R1) 3.12 3.12 3.08 3.11 3.23
Pivot Point 3.04 3.04 3.02 3.03 3.04
Support 1 (S1) 2.91 2.96 2.87 2.90 2.77
Support 2 (S2) 2.83 2.91 2.82 2.76
Support 3 (S3) 2.70 2.83 2.74
Support 4 (S4) 2.69